Sucampo Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Bethesda MD United States (1996)
Status: Acquired by Mallinckrodt (2013) (2017)

Organization Overview

First Clinical Trial
2005
NCT00380250
First Marketed Drug
2000
unoprostone isopropyl (rescula)
First NDA Approval
2006
lubiprostone (amitiza)
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sucampo AG | Sucampo Pharma Americas, LLC | Sucampo Pharmaceuticals, Inc. | SUCAMPO PHARMA LLC